Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Translational Development Acquisition (TDAC) Net Cash Flow (2024 - 2026)

Translational Development Acquisition's Net Cash Flow history spans 3 years, with the latest figure at -$5157.0 for Q1 2026.

  • On a quarterly basis, Net Cash Flow rose 97.77% to -$5157.0 in Q1 2026 year-over-year; TTM through Mar 2026 was -$281970.0, a 100.16% decrease, with the full-year FY2025 number at -$408387.0, down 193.63% from a year prior.
  • Net Cash Flow came in at -$5157.0 for Q1 2026, up from -$17363.0 in the prior quarter.
  • The five-year high for Net Cash Flow was $174.4 million in Q4 2024, with the low at -$231574.0 in Q1 2025.
  • Historically, Net Cash Flow has averaged $24.9 million across 3 years, with a median of -$17363.0 in 2025.
  • Biggest five-year swings in Net Cash Flow: plummeted 145.77% in 2025 and later surged 97.77% in 2026.
  • Year by year, Net Cash Flow stood at $174.4 million in 2024, then plummeted by 100.01% to -$17363.0 in 2025, then soared by 70.3% to -$5157.0 in 2026.
  • Business Quant data shows Net Cash Flow for TDAC at -$5157.0 in Q1 2026, -$17363.0 in Q4 2025, and -$88105.0 in Q3 2025.